Request Demo

Last update 20 Mar 2025

Esmolol Hydrochloride

Last update 20 Mar 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(±)-esmolol, (±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate, 3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester

+ [16]

Target

β1-adrenergic receptor

Action

antagonists

Mechanism

β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [1]

Active Indication

Diabetic foot ulcerVentricular ArrhythmiaHypertension+ [2]

Inactive Indication-

Originator Organization

Baxter International, Inc.

Active Organization

Baxter Healthcare Corp.

Maruishi Pharmaceutical Co., Ltd.

NovaLead Pharma Pvt Ltd.

+ [1]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

United States (31 Dec 1986),

HypertensionTachycardia, SupraventricularTachycardia

Regulation-

Structure/Sequence

Molecular FormulaC16H26ClNO4

InChIKeyGEKNCWBANDDJJL-UHFFFAOYSA-N

CAS Registry81161-17-3

View All Structures (2)

181

Clinical Trials associated with Esmolol Hydrochloride

ChiCTR2500096874

/ SuspendedNot ApplicableIIT

The effects of esmolol on intraoperative stress response and inflammatory response in orthopedic surgery patients

Start Date13 Feb 2025

Sponsor / Collaborator-

CTRI/2024/11/076120

/ Not yet recruitingNot ApplicableIIT

Comparitive study of esmolol and labetalol in attenuation of pressor response to laryngoscopy and endotracheal intubation in patients posted under general anaesthesia:a randomised double blind study. - NIL

Start Date10 Nov 2024

Sponsor / Collaborator-

NCT06635707

/ Not yet recruitingNot ApplicableIIT

The Study on the Efficacy and Safety of Using Urapidil Alone or in Combination With Esmolol for the Treatment of Acute Hypertensive Intracerebral Hemorrhage: A Prospective, Open-label, Observational, Multicenter Research

The objective of this study is to investigate the efficacy and safety of urapidil monotherapy versus the combination of esmolol in treating participants with acute hypertensive intracerebral hemorrhage through a prospective, open-label, observational, multicenter clinical trial, aiming to provide guidance for clinicians in formulating rational treatment plans.

Start Date01 Nov 2024

Sponsor / Collaborator

Qianfoshan Hospital of Shandong Province

100 Clinical Results associated with Esmolol Hydrochloride

100 Translational Medicine associated with Esmolol Hydrochloride

100 Patents (Medical) associated with Esmolol Hydrochloride

2,341

Literatures (Medical) associated with Esmolol Hydrochloride

01 Mar 2025·International Journal of Diabetes in Developing Countries

Effect of patient and wound characteristics on diabetic foot ulcer healing in phase 3 study of novel topical esmolol hydrochloride

Author: Deshpande, Supreet K. ; Singh, Raveena ; Kulkarni, Sudhir A. ; Adhikari, Umanath ; Rastogi, Ashu

Novel topical esmolol is shown to significantly improve wound healing than standard of care.Certain patient-related factors especially anemia and poor glycemic control may impede wound healing.To study whether novel topical esmolol may circumvent patient-related factors to improve wound healing in diabetic foot ulcer (DFU).The present study is a double-blind, vehicle (placebo)-controlled, randomized clin. trial in subjects with non-infected DFU of University of Texas grade 1A and 1C.Participants were randomized to receive either topical esmolol gel (Galnobax) with standard of care (SoC), SoC only, and vehicle (Placebo) with SoC in 3:3:1 proportion.The hematol. and biochem. parameters were evaluated at the screening visit and at every 4 wk after randomization during treatment phase and at the end of the study (EOS).Outcome was the proportion of complete ulcer closure with reference to baseline Hb, albumin, and HbA1c during the 12-wk treatment phase.A total of 176 subjects were included.Ninety-four out of 140 participants (67.1%) had anemia at baseline.Among anemic participants, 57.4% ulcers closed in the Galnobax group whereas 42.6% closed in the SoC only group during the 12-wk treatment phase (p = 0.148, OR = 1.823, 95% CI = 0.80-4.13).One-third participants reported albumin < 4.0 g/dL.Among participants having albumin < 4.0 g/dL (one-third of participants), the proportion of ulcer closure was 60.9% in the Galnobax group compared to 42.1% in the SoC only group (p = 0.225, OR = 2.139, 95% CI = 0.62-7.37).The proportion of ulcer closure in Galnobax with the SoC group was higher (72.5%) compared to the SoC only group (43.5%) (p = 0.0067, OR = 3.427, 95% CI = 1.38-8.48) in participants with poor glycemic control (HbA1c > 8%).Conclusions: Novel topical esmolol with SoC treatment exhibited significant DFU healing independent of patient-related factors including anemia, hypoalbuminemia, and poor glycemic control.

01 Feb 2025·International Immunopharmacology

Esmolol upregulates the α7 nAChR/STAT3/NF-κB pathway by decreasing the ubiquitin and increasing the ChAT+CD4+ T lymphocyte to alleviate inflammation in septic cardiomyopathy

Article

Author: Wang, Fuhua ; Xing, Jinyan ; Han, Xiaoning ; Xue, Ping ; Liu, Ying ; Wang, Jue

Esmolol has been demonstrated to mitigate inflammation damage and T lymphocyte apoptosis in septic cardiomyopathy. It has been established that the activation of α7 nicotinic acetylcholine receptor (nAChR) by cluster of differentiation 4(CD4) ⁺ T lymphocytes expressing choline acetyltransferase (ChAT) can prevent excessive inflammation and reduce splenocyte apoptosis in septic cardiomyopathy. Given the similar anti-inflammatory effects, we hypothesized that esmolol might be associated with α7 nAChR and thereby exert its cardioprotective functions. In the cecal ligation puncture (CLP)-induced rat septic cardiomyopathy model, esmolol was found to attenuate myocardial injury as evidenced by Hematoxylin and Eosin (HE) staining, terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay, and the reduced concentration of interleukin (IL)-1, IL-6, and Tumor Necrosis Factor (TNF)-α detected by enzyme-linked immunosorbent assay (ELISA). Western blotting (WB) revealed that esmolol enhanced the expression of α7 nAChR, elevated the level of Phosphorylated-Signal transducer and activator of transcription 3 (P-STAT3)/STAT3, and decreased the level of Nuclear factor-κB (NF-κB), which led to the reduction of plasma IL-1, IL-6, and TNF-α. Methyl lycaconitine Citrate (MLA, an α7 nAChR inhibitor) suppressed the level of P-STAT3/STAT3, while stattic (a STAT3 inhibitor) inhibited the level of P-STAT3/STAT3 and up-regulated the expression of NF-κB. Real-time quantitative PCR (RT-qPCR) results indicated no significant difference in the mRNA level of α7 nAChR, but immunofluorescence and WB results verified the upregulation of α7 nAChR by esmolol and the reduction of ubiquitin induced by esmolol. In the spleen, esmolol decreased splenocyte apoptosis and increased the expression of α7 nAChR as shown by immunofluorescence. In isolated CD4⁺ T cells obtained through magnetic cell separation, esmolol enhanced the expression of ChAT mRNA. In conclusion, esmolol upregulates α7 nAChR by decreasing ubiquitin and increasing ChAT⁺CD4⁺ T lymphocytes and then increases the P-STAT3/STAT3 which inhibits NF-κB thus alleviating inflammation in septic cardiomyopathy.

01 Feb 2025·Chromatographia

Enantioseparations of the Six Basic Drugs by MIL-100(Fe)-Modified Open-Tubular Columns in Capillary Electrochromatography

Author: Yu, Tao ; Miao, Pandeng ; Shao, Xiaozhen ; Du, Yingxiang ; Yang, Ke ; Xu, Guangfu ; Chen, Jiaquan

Abstract: Metal-organic frameworks (MOFs) have a wide range of applications in separation and anal. sciences due to their unique structures.MIL-100(Fe) was immobilized on the inner wall of the capillary column based on the immobilized cysteine (Cys)-triggered in situ growth (ICISG) strategy.By applying this column to capillary electrophoresis, a novel enantioselective separation system based on MIL-100(Fe) nanomaterial was established.By utilizing lactobionic acid (LA) as the chiral selector and optimizing the exptl. conditions such as buffer pH, LA concentration and the methanol addition ratio, the CEC system demonstrated a significantly enhanced enantioseparation ability for six basic drugs.The modified capillary column was characterized by scanning electron microscope, energy-dispersive X-ray spectroscope and X-ray diffractometer.The exptl. results showed that MIL-100(Fe) was successfully grown on the inner wall of the capillary column.In the present study, the repeatability of the coated column was investigated and the relative standard deviations of the resolution and the migration time for intra-day, inter-day and inter-column were within 8%, proving the good repeatability of the coated column.

News (Medical) associated with Esmolol Hydrochloride

04 Jan 2024

·www.biospace.com

Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023

More new product innovations in 2023, as compared to 26 in 2022 13 new products launched in the fourth quarter of 2023 BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) today announces that it has launched 39 new retail and injectable medicines in 2023, as compared to 26 new launches in 2022. In the fourth quarter of 2023, Amneal launched 13 new products, including 5 injectables. New injectable products added include potassium phosphate vials, tranexamic acid and esmolol intravenous bags. These launches provide a strong foundation for higher injectable revenues going forward. In addition, Amneal launched several key new retail products in the fourth quarter, including spironolactone suspension with 180-day exclusivity, valsartan and hydrochlorothiazide tablets, and icosapent capsules. “We are pleased to have brought an impressive number of new products to market in 2023,” said Dr. Srinivas Kone, Senior Vice President, Generics R&D. “Our R&D portfolio prioritizes complex and high-value products that provide better access to affordable medicines for providers and patients.” About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a fully integrated global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 270 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit . Cautionary Statement on Forward-Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations, including international expansion; expected or estimated operating results and financial performance; the Company’s growth prospects and opportunities as well as its strategy for growth; product development and launches; the successful commercialization and market acceptance of new products, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our ability to manage our growth through acquisitions and otherwise; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; our ability to complete the proposed holding company reorganization on the anticipated timeline or at all and to realize the expected benefits of such reorganization; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our ability to secure satisfactory terms when negotiating a refinancing or other new indebtedness; our dependence on third-party agreements for a portion of our product offerings; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of product liability and other claims against us by consumers and other third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties, including recent events affecting the financial services industry; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; the impact of global economic, political or other catastrophic events; our ability to attract, hire and retain highly skilled personnel; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A Common Stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof. View source version on businesswire.com: Contacts Investors: Anthony DiMeo Head of Investor Relations anthony.dimeo@amneal.com Source: Amneal Pharmaceuticals, Inc. View this news release online at:

20 Dec 2022

·www.biospace.com

Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

- 8 new product launches in Q4 closes out another successful year of innovation - First approval of a large volume bag product signals further expansion of injectables business BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the Company has successfully launched 26 new generic products in 2022. In the fourth quarter of 2022, the Company launched 8 new generic products, including clindamycin phosphate gel 1%, ipratropium bromide nasal sprays, and prednisolone sodium phosphate oral solution. “2022 was another successful year of innovation for Amneal. Across the portfolio we continue to innovate, further expand our portfolio of essential medicines, and drive incremental impact and benefit for health care professions and their patients. Looking to 2023, we expect more than 30 new product launches,” said Chirag Patel and Chintu Patel, Amneal Co-Chief Executive Officers. In addition, Amneal also announced it received Abbreviated New Drug Application approval from the U.S. Food and Drug Administration (“FDA”) for its first large volume bag, esmolol hydrochloride in sodium chloride injection. Harsher Singh, SVP for Amneal Biosciences, stated, “We are seeing continued momentum in expanding our injectables business. We are excited about this first ready to use bag approval utilizing one of our new manufacturing sites and look forward to more over the coming months.” Esmolol hydrochloride in sodium chloride injection is indicated for tachycardia. For full prescribing information, see package insert located here. According to IQVIA®, U.S. annual sales for this product for the 12 months ended October 2022 were $57 million. About Amneal Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit . Cautionary Statement on Forward-Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance, the Company’s growth prospects and opportunities as well as its strategy for growth; product development and launches; the successful commercialization and market acceptance of new products, and expenditures. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words are intended to identify estimates and forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry, in general, specifically from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our ability to manage our growth through acquisitions and otherwise; our dependence on the sales of a limited number of products for a substantial portion of our total revenues; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods and any associated supply chain disruptions; existing and future legal proceedings, the outcome of which are uncertain and may divert management resources and require us to incur substantial defense or settlement payments and costs; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; the impact of severe weather; the impact of the ongoing COVID-19 pandemic, and the emergence of variant strains; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of product liability and other claims against us by consumers and other third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to FDA product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our dependence on third-party agreements for a portion of our product offerings; the impact of global economic conditions, including any economic effects stemming from adverse geopolitical events, an economic downturn, inflation and rising interest rates; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A Common Stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Drug Approval

100 Deals associated with Esmolol Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00644	Esmolol Hydrochloride	C07AB09	DB00187

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetic foot ulcer	India	NovaLead Pharma Pvt Ltd.	24 Apr 2024
Ventricular Arrhythmia	Japan	Maruishi Pharmaceutical Co., Ltd.	08 Oct 2002
Hypertension	United States	Baxter Healthcare Corp.	31 Dec 1986
Tachycardia	United States	Baxter Healthcare Corp.	31 Dec 1986
Tachycardia, Supraventricular	United States	Baxter Healthcare Corp.	31 Dec 1986

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic foot ulcer	Phase 2	United States	NovaLead Pharma Pvt Ltd.	20 Feb 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04356352 (CTgov)	Phase 2/3	Pain \| Injection Site Reaction	33	Lidocaine (Lidocaine)	cqvexqryge(hqjgbzwtnl) = epgkgszqng nttlfhsmdj (xtbkjwvrac, wnwydslcdu - aytsogesjx) View more	-	19 Sep 2024
				Esmolol (Esmolol)	cqvexqryge(hqjgbzwtnl) = fxkcbegtoo nttlfhsmdj (xtbkjwvrac, lrrldhlicj - hromhafafe) View more
NCT01113515 (CTgov)	Phase 1/2	Diabetic foot ulcer	44	Placebo gel (Placebo)	xqpdmbgzcb(muwtykudak) = vgytnajyts gwyrlkjmfh (tjfnsilxsu, nfpiiixfaz - zygocaovcv) View more	-	20 May 2024
				Esmolol hydrochloride (Galnobax 20% QD)	xqpdmbgzcb(muwtykudak) = ftacjudpzi gwyrlkjmfh (tjfnsilxsu, eouddevrrg - ejyrjfiqmm) View more
NCT03998436 (CTR/2018/11/016295 \| ###DELETE, CTgov)	Phase 3	Diabetic foot ulcer	176	Esmolol Hydrochloride (Galnobax® 14% Gel Plus SoC)	bmciqoifmv(apiecxoipl) = ncdhxwiprn wlzskjwwcf (wttivmkukb, cgocxhzlyi - juroiixesk) View more	-	22 Sep 2023
				Only Standard of Care (SoC Only)	bmciqoifmv(apiecxoipl) = satkvqdaxb wlzskjwwcf (wttivmkukb, xwcpfrlzaj - hnqsnfmnno) View more
CTRI/2013/07/003838 \| NCT01113515 (Pubmed)	Phase 1/2	Diabetic foot ulcer	-	Galnobax 14%	nklrhhkike(jbqnsvuixv) = lkagrjeaxy qnsnxxnksx (jyswyrdzcr ) View more	-	16 Oct 2022
				Galnobax 20%	nklrhhkike(jbqnsvuixv) = aogoiwbtgc qnsnxxnksx (jyswyrdzcr ) View more
NCT02369900 (Pubmed)	Phase 2	Shock, Septic	40	Esmolol	(dpskyiukiz) = bpgveuobwz chviuvlqsj (pjdqsefigo )	-	27 Dec 2021
				Placebo	(dpskyiukiz) = jujxzsebgt chviuvlqsj (pjdqsefigo )
ERS2021	Not Applicable	Heart Failure	-	Landiolol	(inojbgkdxv) = eslnxygeme tbbxejlyep (pvkdfcfpio )	Positive	05 Sep 2021
				Esmolol	(inojbgkdxv) = jybhxuagjq tbbxejlyep (pvkdfcfpio )
NCT02369900 (CTgov)	Phase 2	Shock, Septic \| Hypotension \| Tachycardia	40	Esmolol (Esmolol Infusion)	jpeyvplwwu(xverwhalqb) = efrjusavct orrshpmfqq (tmqvfhtlxo, lcstffiirz - hfzluelpyi) View more	-	28 Jun 2021
				saline (Standard Care, Saline)	jpeyvplwwu(xverwhalqb) = dhtytwldaa orrshpmfqq (tmqvfhtlxo, cdpsgskghn - lqgvpeusyd) View more
NCT02466542 (Pubmed \| Eur J Anaesthesiol)	Phase 4	-	-	Esmolol infusion	(gfilacrfio) = lzsqddfplc xpdhvrhpuk (kzztjvxqip, -13.4 to -0.31)	Positive	08 Apr 2021
NCT03661346 (CTgov)	Phase 2	Hemorrhage \| Chronic sinusitis	28	Esmolol (Esmolol)	epkpmmmhiy(alwwavvrec) = uddiqblist rrebrnmkrt (igimfcxuue, nuojzciiba - xsoibrfcrh) View more	-	08 Feb 2021
				Labetalol (Labetalol)	epkpmmmhiy(alwwavvrec) = swryqlfpaf rrebrnmkrt (igimfcxuue, tmiiddjfxm - elwjiefneu) View more
NCT02068287 (ESMOSEPSIS, Pubmed \| Crit Care) Manual	Phase 2	Shock, Septic	9	Esmolol	ggbkavgevk(fmmjnvzcok) = decrease from 4.2 to 2.9 l/min/m-2 uorjnbytrb (soitujwtxq ) View more	Positive	07 Jan 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Esmolol Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation